DRL posts Q2 FY17 and H1FY17 results
In Q2 FY17, EBITDA is at Rs 6.4 billion and profit after tax at Rs 2.9 billion
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
DRL
DRL’s migraine drug ZEMBRACE SymTouch launched in US
It is available in a box containing 4 autoinjectors
DRL signs MoU with LSSSDC and VIPER
The MoU is aimed at fostering market research collaboration that will help align educational courses to industry requirements
Sales rep files sexual harassment claims against DRL, Promius Pharma
The case was filed on July 31, 2015 and the nature of the suit is civil rights-employment
A woman sales representative from…
DRL Laboratories signs commercialisation deal with Hatchtech
DRL will pay Hatchtech an upfront amount of $10 million, up to $ 50 million
DRL ink pact with Purdue varsity for drug research
The intent of the MoU is to forge a strong strategic partnership in a range of research areas and novel technologies in the field…
DRL unveils new corporate brand identity
The new identity speaks of Dr Reddy’s constant endeavour to understand the unmet and under-met needs of patients, and the swift…